Figures computed from official regulatory filings — .
Ownershipinsiders 57.11% · institutions 0%
In EUR · as of Oct 26, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ONCODESIGN PRECISION MEDICINE S.A. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers under PROMETHE brand; Nanocyclix, a kinase inhibitors, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
Market information source · Oct 26, 2026
Open-market timeline · full history
3 buys2 sellsbar = usd volume, √ scaleclick a period to filter the table
| JAN HOFLACK | Buy | $129.8K | conv 56First in 12mo | AMF |
| SAS P.C.G Société par actions simplifiée | Sell | $172.9K | AMF |
| KARINE LIGNEL | Buy | $172.9K | conv 60Cluster | AMF |
| SAS P.C.G Société par actions simplifiée | Sell | $129.8K | AMF |
| P.C.G. société civile | Buy | $116.7K | conv 33First in 12mo | AMF |